Oncologist Lewis Silverman on Revlimid for Patients with Myelodysplastic Syndrome

Article

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.

Revlimid is currently approved for patients with a specific type of MDS that contains a chromosomal abnormality called deletion 5q.

The phase 3 trial,which was reported at the 2014 American Society of Hematology, includes patients with MDS who do not have the chromosomal abnormality but have low-risk disease.

The purpose of the study was to find out if Revlimid could reduce the number of red blood cell transfusions needed by anemic (transfusion-dependent) patients with low- or intermediate-risk MDS without a deletion 5q chromosome abnormality.

Silverman says the study confirms that about a quarter of patients who do not have the deletion 5q abnormality can become transfusion independent, and the duration of treatment response is about eight or nine months.

Related Videos
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content